Aviado · Research
Longevity Daily
Tuesday, May 5, 2026
Listen
Today's Brief
Canada's approval of donanemab marks a genuine milestone: it's the first Alzheimer's therapy with evidence supporting stopping treatment once amyloid plaques are cleared. Early clinical signals from Aspen Neuroscience's personalized Parkinson's cell therapy and a new mechanism linking protein aggregation to neuroinflammation make today's cognitive section unusually rich. A surprising ADNI finding challenges the omega-3/brain health narrative, and our Aviado analysis shows how to use bloodwork to confirm whether boswellia is actually working for you. Peter Attia's latest AMA cuts through the noise on NAD supplements and dementia risk — essential listening for health optimizers.
10 stories1 trials1 Aviado original
Cognitive Health & Neuroprotection
Canada Approves Donanemab — the First Alzheimer's Drug With Evidence to Stop Treatment Once Plaques Are Cleared
Eli Lilly's donanemab has received Canadian regulatory approval for early-stage Alzheimer's disease, becoming the first amyloid-targeting therapy with clinical evidence supporting stopping treatment once plaques are eliminated. In pivotal trials, the drug slowed cognitive and functional decline by approximately 35% in patients with low-to-moderate tau burden. The 'stop-when-done' model is a meaningful departure from how most chronic neurological conditions are managed — suggesting Alzheimer's pathology may be modifiable rather than requiring indefinite treatment. Access and pricing remain significant barriers, and the therapy is best suited for early-stage patients where amyloid burden is still catchable.
Read more →Personalized Cell Therapy Shows Early Signs of Brain Restoration in Parkinson's Patients
Aspen Neuroscience presented early clinical data at the AD/PD 2026 conference in Copenhagen suggesting their personalized iPSC-derived neuron replacement therapy may not just slow Parkinson's progression — it may partially restore lost function. This matters because most neurodegenerative therapies aim to slow decline; genuine restoration would be a paradigm shift. The data is early and sample sizes are small, but the signal warrants close attention as the trial matures.
Read more →Scientists Find the Chemical Switch That Hijacks Brain Immunity in Alzheimer's — and Blocking It Helped Mice
Researchers have identified how amyloid protein aggregation in Alzheimer's disease triggers runaway neuroinflammation: a chemical modification called S-nitrosylation causes the immune protein STING to become chronically overactivated, compounding the cognitive damage from plaques alone. Blocking this modification in mouse models significantly reduced harmful neuroinflammation while preserving normal immune function. This opens a new therapeutic avenue targeting the inflammation pathway rather than amyloid clearance alone — though human applications are years away.
Read more →Supplements & Compounds
ADNI Data Delivers a Surprise: Omega-3 Supplements Were Linked to Worse Cognitive Trajectories
A new analysis of the Alzheimer's Disease Neuroimaging Initiative (ADNI) database — one of the most rigorous long-running studies of brain aging — found that omega-3 supplement users showed faster, not slower, changes in cognition and Alzheimer's-related brain biology over time. This is observational data, not an RCT, and reverse causation is a strong confounder (people already noticing cognitive changes may seek out omega-3s). That said, it's a meaningful challenge to the common assumption that supplemental omega-3s protect cognitive aging, and worth monitoring as more evidence accumulates.
Read more →Magnesium L-Threonate Crosses the Blood-Brain Barrier — Here's the Science Behind the Claims
Most magnesium forms can't meaningfully penetrate the blood-brain barrier, limiting their impact on cognitive health — but Magnesium L-threonate (Magtein®) was specifically engineered to overcome this, and the mechanistic case for how it elevates brain magnesium levels to support synaptic density and neuroplasticity is increasingly well-characterized. These two structural features of cognitive reserve are among the clearest targets for slowing age-related brain decline. Note that this content is authored by the manufacturer's R&D director, so treat it as a useful mechanistic primer while seeking independent replication.
Read more →Boswellia's Anti-Inflammatory Signal Is Real — But Your Bloodwork Will Tell You If You're Actually Responding
Multiple trials confirm boswellia serrata can reduce inflammatory cytokines like TNF-α and IL-6 by 30–50% in some people — but produces essentially no measurable effect in others, and you can't tell which category you're in without testing. Aviado's analysis recommends a practical protocol: 500–1,000 mg of standardized extract (≥30% boswellic acids, ≥10% AKBA) for 90 days, with hsCRP and TNF-α measured before and after. A 20–30% drop confirms you're a responder; if not, you've learned that early and can redirect your stack before wasting months on something not working for your biology.
Read the full Aviado analysis →Research & Papers
Biological Age Clocks Are Research Tools, Not Consumer Products — Scientists Push Back
Epigenetic clocks and other biological age tests can reliably identify population-level patterns about what accelerates or slows aging — but they produce unreliable results at the individual level and don't yet meet the standards required of clinical diagnostics, according to researchers writing in The Conversation. If you've paid for a consumer bio-age test, your score is a probabilistic estimate with meaningful uncertainty, not a measurement you can act on with confidence. The authors argue these tools should remain in the research setting until individual-level precision is validated.
Read more →The Thymus Gets a Scientific Reappraisal: New Research Links This Shrinking Organ to Longevity and Cancer Defense
The thymus — which involutes dramatically after puberty and was long considered a biological afterthought — is being recast by a growing body of research as a critical regulator of immune aging across the lifespan. Studies now suggest thymic decline is a key upstream driver of the immune deterioration that raises vulnerability to both infections and malignancies with age. Researchers are actively exploring interventions targeting thymic regeneration as a legitimate longevity strategy.
Read more →Lifestyle & Nutrition
Peter Attia's AMA #84: The Real Evidence on Dementia Prevention, NAD Supplements, and Strength Training
In his latest Ask Me Anything, Peter Attia works through high-yield territory for health optimizers: interpreting family history for cardiovascular risk, practical dementia risk reduction strategies, strength training efficiency, and — directly relevant to supplement users — an honest evidence review of NAD precursors like NMN and NR. Attia applies characteristic clinical skepticism rather than advocacy, making his take on NAD especially worth hearing if you're currently dosing it or considering it. This is a reliable calibration tool for separating signal from noise in the longevity space.
Read more →Industry & Policy
Human Longevity Pivots to Consumers With $25,000 Health Nucleus Plan After Leadership Shakeup
Following executive turnover, genomics company Human Longevity has hired a new CTO and unveiled an expanded consumer-facing offering: a $25,000 package through its Health Nucleus platform that includes whole-body MRIs and a comprehensive biomarker battery. The move signals a deliberate push into the premium direct-to-consumer longevity diagnostics market, putting it in competition with platforms like Function Health at the high end of the consumer health optimization space.
Read more →